Enanta Pharmaceuticals, Inc.

Enanta discovers and develops small molecule drugs for viral infections and liver diseases. Its pipeline includes EDP-514 for HBV treatment, EDP-938/323 for RSV, EDP-235 for human coronaviruses, and Glecaprevir for HCV treatment. Glecaprevir is already marketed for HCV. The company has a partnership with Abbott Laboratories to develop HCV NS3 inhibitors. Enanta was founded in 1995 and is headquartered in Massachusetts.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

15.1 USD

Potential

111%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0

Enanta Pharmaceuticals, Inc.

Overview

Strengths

Weaknesses

Key Financial Data